262 related articles for article (PubMed ID: 23673278)
1. The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain.
Uhelski ML; Cain DM; Harding-Rose C; Simone DA
Neuroscience; 2013 Sep; 247():84-94. PubMed ID: 23673278
[TBL] [Abstract][Full Text] [Related]
2. Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury.
Johanek LM; Simone DA
Pain; 2004 Jun; 109(3):432-442. PubMed ID: 15157704
[TBL] [Abstract][Full Text] [Related]
3. The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms.
Potenzieri C; Harding-Rose C; Simone DA
Brain Res; 2008 Jun; 1215():69-75. PubMed ID: 18486111
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of C-fiber nociceptors in mice with sickle cell disease is decreased by local inhibition of anandamide hydrolysis.
Uhelski ML; Gupta K; Simone DA
Pain; 2017 Sep; 158(9):1711-1722. PubMed ID: 28570479
[TBL] [Abstract][Full Text] [Related]
5. Local application of the cannabinoid receptor agonist, WIN 55,212-2, to spinal trigeminal nucleus caudalis differentially affects nociceptive and non-nociceptive neurons.
Papanastassiou AM; Fields HL; Meng ID
Pain; 2004 Feb; 107(3):267-275. PubMed ID: 14736589
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy.
Uhelski ML; Khasabova IA; Simone DA
J Neurophysiol; 2015 Mar; 113(5):1501-10. PubMed ID: 25505113
[TBL] [Abstract][Full Text] [Related]
7. Tumor-evoked sensitization of C nociceptors: a role for endothelin.
Hamamoto DT; Khasabov SG; Cain DM; Simone DA
J Neurophysiol; 2008 Oct; 100(4):2300-11. PubMed ID: 18684911
[TBL] [Abstract][Full Text] [Related]
8. Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain.
Khasabova IA; Holman M; Morse T; Burlakova N; Coicou L; Harding-Rose C; Simone DA; Seybold VS
Neurobiol Dis; 2013 Oct; 58():19-28. PubMed ID: 23644187
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
10. CB
Zheng T; Zhang R; Zhang T; Zhang MN; Xu B; Song JJ; Li N; Tang HH; Wang P; Wang R; Fang Q
Brain Res; 2018 Feb; 1680():155-164. PubMed ID: 29274880
[TBL] [Abstract][Full Text] [Related]
11. Changes in response properties of nociceptors and dorsal horn neurons in a murine model of cancer pain.
Simone DA; Khasabov SG; Cain DM; Hamamoto DT; Khasabova IA
Fiziol Zh (1994); 2011; 57(5):75-7. PubMed ID: 22185016
[No Abstract] [Full Text] [Related]
12. Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia.
Hamamoto DT; Giridharagopalan S; Simone DA
Eur J Pharmacol; 2007 Mar; 558(1-3):73-87. PubMed ID: 17250825
[TBL] [Abstract][Full Text] [Related]
13. Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain.
Liu C; Walker JM
J Neurophysiol; 2006 Dec; 96(6):2984-94. PubMed ID: 16943316
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain.
Ahmed MM; Rajpal S; Sweeney C; Gerovac TA; Allcock B; McChesney S; Patel AU; Tilghman JI; Miranpuri GS; Resnick DK
Spine J; 2010 Dec; 10(12):1049-54. PubMed ID: 20920894
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of protective effects of non-selective cannabinoid receptor agonist WIN 55,212-2 against the nitroglycerine-induced acute and chronic animal models of migraine: A mechanistic study.
Mohammadi Vosough E; Baradaran Rahimi V; Masoud SA; Mirkarimi HR; Demneh MK; Abed A; Banafshe HR; Askari VR
Life Sci; 2019 Sep; 232():116670. PubMed ID: 31330139
[TBL] [Abstract][Full Text] [Related]
16. Effects of WIN 55,212-2 (a synthetic cannabinoid CB1 and CB2 receptor agonist) on the anticonvulsant activity of various novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice.
Florek-Luszczki M; Wlaz A; Zagaja M; Andres-Mach M; Kondrat-Wrobel MW; Luszczki JJ
Pharmacol Biochem Behav; 2015 Mar; 130():53-8. PubMed ID: 25592741
[TBL] [Abstract][Full Text] [Related]
17. Antineoplastic effect of WIN 55,212-2, a cannabinoid agonist, in a murine xenograft model of gastric cancer.
Oh JH; Lee JY; Baeg MK; Han KH; Choi MG; Park JM
Chemotherapy; 2013; 59(3):200-6. PubMed ID: 24335109
[TBL] [Abstract][Full Text] [Related]
18. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain.
Kehl LJ; Hamamoto DT; Wacnik PW; Croft DL; Norsted BD; Wilcox GL; Simone DA
Pain; 2003 May; 103(1-2):175-86. PubMed ID: 12749972
[TBL] [Abstract][Full Text] [Related]
19. Involvement of cannabinoid CB1 receptors in the antinociceptive effect of dipyrone.
Elmas P; Ulugol A
J Neural Transm (Vienna); 2013 Nov; 120(11):1533-8. PubMed ID: 23784345
[TBL] [Abstract][Full Text] [Related]
20. Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist.
Bilir KA; Anli G; Ozkan E; Gunduz O; Ulugol A
Clin Exp Dermatol; 2018 Jul; 43(5):553-558. PubMed ID: 29424035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
